PulseSight Therapeutics, which is developing non-viral gene therapies for retinal diseases, has launched with seed financing from Pureos Bioventures and ND Capital, according to a press release.
“PulseSight is developing highly promising compounds that have the potential to overcome the limitations of current treatments for wet [age-related macular degeneration] and viral gene therapies under development, with strong efficacy while reducing the burden of administration,” Judith Greciet, CEO of PulseSight, told Healio. “PulseSight is heading to the clinical stage with its two